1. Verification of Wild-Type EGFR Status in Non–Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases 
Yi-Lin Chen, Cheng-Chan Lu, Shu-Ching Yang, Wen-Pin Su, Ya-Lan Lin, Wan-Li Chen, Wenya Huang, Wu-Chou Su, Nan-Haw Chow, Chung-Liang Ho 
The Journal of Molecular Diagnostics 
Volume 16, Issue 5, Pages (September 2014)
DOI: /j.jmoldx
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

2. Figure 1
Representative cases of different amplification efficiency using EGFR IVD Kit: true amplification (A), equivocal amplification (B), and no amplification (C). Norm. Fluoro., normal fluorescence.
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

3. Figure 2
Of the equivocal cases (A–G), five (A–E) came from the EGFR RUO Kit and two (F and G) came from the EGFR IVD Kit. They were further investigated using direct-sequencing and PNA-sequencing. For PCR amplification plots, control runs are noted with black arrows, and sample runs are noted with blue arrows. For sequencing data, wild-type positions of interest are noted with black arrows, and mutant positions are noted with red arrows. Del, deletion; Ex, exon; ins, insertion; Norm. Fluoro., normal fluorescence.
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

4. Figure 3
Exploration of the specificity of mutation detection by the EGFR IVD Kit. H773_V774insPH in exon 20, for which a specific primer sequence was not designed in the commercial kit. Further study using cloned DNA fragments shows that the upward curve most likely results from a cross-reaction between similar, but nonidentical, sequences. Norm. Fluoro., normal fluorescence.
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

5. Figure 4
Example of a partial response to TKI treatment. The patient is an 85-year-old woman with primary lung adenocarcinoma. The CT images at pretreatment (A) and post-treatment (B) stages. The tumor size decreased from 5to 2.7 cm (46%) after 8 months of TKI treatment.
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions